Colon cancer is divided into four main stages based on how deeply the tumor has grown into the colon wall, whether it has reached nearby lymph nodes, and whether it has spread to distant organs. The stages range from Stage 1 (cancer confined to the inner layers of the colon) to Stage 4 (cancer that has spread to other parts of the body). There is also a Stage 0, sometimes called carcinoma in situ, where abnormal cells sit only in the innermost lining and haven’t yet invaded deeper tissue.
Staging uses the TNM system developed by the American Joint Committee on Cancer. T describes tumor depth, N describes lymph node involvement, and M describes whether cancer has metastasized to distant sites. Together, these three factors determine the overall stage and shape every treatment decision that follows.
How Colon Cancer Is Staged
After a colonoscopy finds cancer, your medical team needs to figure out how far it has spread before recommending treatment. This typically involves a CT scan of the chest, abdomen, and pelvis to look for cancer in the lymph nodes, liver, lungs, or other organs. Blood tests check for anemia from long-term tumor bleeding and measure liver function, since the liver is a common destination for spreading colon cancer. A blood marker called CEA is also measured; while it can’t diagnose cancer on its own, it serves as a useful baseline to track how well treatment is working later.
Biopsy samples from the colonoscopy or surgery are tested in a lab for molecular features that influence both prognosis and treatment options. One important test checks for mismatch repair status, which reveals how the cancer’s DNA repair system functions. This result affects whether immunotherapy is an option and can also flag Lynch syndrome, a hereditary condition that raises cancer risk for family members.
Stage 1: Cancer in the Inner Colon Wall
In Stage 1, the tumor has grown past the innermost lining of the colon into the submucosa (the layer just beneath) or into the muscular wall itself, but no further. No lymph nodes are involved, and the cancer hasn’t spread anywhere else. This is often discovered during a routine colonoscopy or screening, and many people have no symptoms at all.
Treatment is straightforward: surgery to remove the section of colon containing the tumor, along with nearby lymph nodes for examination. Chemotherapy is not needed. After surgery, the standard approach is observation with regular follow-up visits and periodic colonoscopies to watch for recurrence. Five-year relative survival for localized colorectal cancer (which includes Stage 1) is 91.3%, according to national data from the SEER program.
Stage 2: Cancer Through the Colon Wall
Stage 2 means the tumor has grown deeper than Stage 1 but still hasn’t reached the lymph nodes. It breaks down into three substages based on exactly how far the cancer extends:
- Stage 2A: The cancer has grown into the outermost layers of the colon wall but hasn’t broken through it.
- Stage 2B: The cancer has grown through the colon wall, including its outer covering, but hasn’t attached to neighboring organs.
- Stage 2C: The cancer has pushed through the wall and grown into nearby tissues or organs.
Treatment always starts with surgery. Whether you need chemotherapy afterward depends on several factors: the substage, the tumor’s mismatch repair status, and whether other high-risk features are present. Many people with Stage 2A cancers skip chemotherapy entirely and move to observation. For Stage 2C, immunotherapy may be recommended alongside chemotherapy for certain tumor types. The decision is more nuanced at this stage than at any other, and it hinges on the specific biology of your tumor rather than a one-size-fits-all protocol.
Stage 3: Cancer in the Lymph Nodes
Stage 3 is defined by one key change: cancer cells have reached nearby lymph nodes. The tumor itself may be any depth, from the submucosa all the way through the colon wall. What matters is lymph node involvement, which signals the cancer has begun using the body’s lymphatic drainage system as a pathway.
Stage 3 is further divided based on how many lymph nodes contain cancer. Stage 3A involves fewer nodes and a shallower tumor. Stage 3B and 3C involve progressively more lymph nodes or a deeper tumor that has grown through the colon wall. Having cancer in 4 or more lymph nodes places you in a higher-risk category than having it in 1 to 3.
Surgery remains the first step, but chemotherapy afterward is recommended for all Stage 3 cancers regardless of other features. Treatment typically lasts 3 to 6 months. For tumors with deficient mismatch repair (a specific DNA repair characteristic found in about 15% of colon cancers), immunotherapy may be combined with chemotherapy as a preferred approach. The five-year relative survival rate for regional colorectal cancer, which corresponds roughly to Stage 3, is 75.2%.
Stage 4: Cancer Has Spread to Distant Organs
Stage 4 means the cancer has metastasized to organs or tissues far from the colon. The liver and lungs are the most common destinations. Cancer can also spread to the peritoneum (the membrane lining the abdominal cavity), distant lymph nodes, and less commonly to the bones, brain, or ovaries. Cancer cells reach these sites by traveling through the bloodstream or lymphatic system, or by growing directly into the peritoneal lining.
Stage 4 has its own substages that reflect where and how widely the cancer has spread:
- Stage 4A: Cancer has spread to one distant organ or set of lymph nodes, but not the peritoneum.
- Stage 4B: Cancer has spread to two or more distant organs, but not the peritoneum.
- Stage 4C: Cancer has reached the peritoneum, with or without involvement of other organs.
When all areas of cancer can be surgically removed, the combination of surgery and systemic therapy (chemotherapy, targeted therapy, or immunotherapy) offers the best outcomes. When surgery isn’t possible, systemic therapy becomes the primary treatment. The specific drugs depend heavily on the tumor’s molecular profile. Tumors with deficient mismatch repair often respond well to immunotherapy, and this may be the preferred first approach. For tumors without that feature, chemotherapy is combined with targeted drugs that block blood vessel growth or, for cancers originating on the left side of the colon, drugs that block a growth signal called EGFR.
Specialized radiation can target individual metastases in the liver, lungs, or bones when needed. The five-year relative survival rate for distant colorectal cancer is 16.9%, though outcomes vary significantly depending on how many organs are involved and how the cancer responds to treatment.
How Genetic Markers Affect Outlook
Beyond the stage itself, certain genetic mutations within the tumor cells play a meaningful role in prognosis. Two mutations in particular stand out. Tumors carrying KRAS mutations or BRAF mutations tend to have worse outcomes in patients with Stage 2 or Stage 3 disease who receive chemotherapy after surgery. BRAF mutations carry a roughly 43% higher risk of death compared to tumors without that mutation, while KRAS mutations are linked to a 25% higher risk.
These mutations also limit treatment options. Patients whose tumors carry KRAS or BRAF mutations don’t respond to EGFR-blocking drugs, which are an important tool in Stage 4 treatment. Interestingly, the negative impact of these mutations appears mainly in tumors that have stable microsatellites (the majority of colon cancers). In the smaller group of tumors with high microsatellite instability, KRAS and BRAF mutations don’t seem to worsen outcomes in the same way, and these cancers often respond well to immunotherapy regardless.
This is why molecular testing at diagnosis matters so much. Two tumors at the same stage can behave very differently depending on their genetic profile, and treatment plans increasingly reflect that complexity.